Clinical trials in Castello De La Plana – page 6

102 clinical trials in Castello De La Plana, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Castello De La Plana at a glance

102

clinical trials

Research sites2

Quick filters

102 trials in Castello De La Plana

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer

Registered drugNo placebo

Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Fulvestrant
Sponsor:Medica Scientia Innovation Research S.L.

Contact Research Centre

Hormone receptor positive breast cancer

Not recruiting

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Palbociclib
Sponsor:ABCSG GmbH

Contact Research Centre

Narcolepsy

Not recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:GBG Forschungs GmbH

Contact Research Centre

Cutaneous lupus erythematosus

Not recruiting

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

HER2 positive breast cancer

Not recruiting

Study on Chemotherapy-Free Treatment with Trastuzumab, Pertuzumab, and T-DM1 for Patients with HER2-Positive Early-Stage Breast Cancer

Registered drugNo placebo

Study on Chemotherapy-Free Treatment with Trastuzumab, Pertuzumab, and T-DM1 for Patients with HER2-Positive Early-Stage Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pertuzumab
Sponsor:Medica Scientia Innovation Research S.L.

Contact Research Centre

Non-small cell lung cancer metastatic

Not recruiting

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Inupadenant Hydrochloride
Sponsor:iTeos Belgium

Contact Research Centre

Gastrointestinal stromal tumour

Not recruiting

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Imatinib
Sponsor:Region Skane

Contact Research Centre

Hormone receptor positive breast cancer+1

Not recruiting

Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

Registered drugNo placebo

Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Neratinib
Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Contact Research Centre

Malignant peritoneal neoplasm+2

Not recruiting

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:pharmaand GmbH

Contact Research Centre

Lung neoplasm malignant

Not recruiting

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Domvanalimab
Sponsor:AstraZeneca AB

Contact Research Centre

Hormone-refractory prostate cancer

Not recruiting

Study Comparing Radium-223 Dichloride with Abiraterone Acetate, Enzalutamide, and Prednisone in Patients with Advanced Prostate Cancer Spread to the Bone

Registered drugNo placebo

Study Comparing Radium-223 Dichloride with Abiraterone Acetate, Enzalutamide, and Prednisone in Patients with Advanced Prostate Cancer Spread to the Bone

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Bayer AG

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Castello De La Plana

What the registry says about research in the country

01 Autoimmune Conditions

Multiple trials exploring treatments for Sjögren's Syndrome and systemic lupus erythematosus, evaluating novel therapies like sibeprenlimab and dapirolizumab pegol for improving disease management and patient outcomes.

Sjögren's Disease Management
Lupus Treatment Studies
Psoriatic Arthritis Research

Focus on long-term safety and effectiveness of new therapeutic approaches for chronic autoimmune conditions.

02 Oncology Research

Comprehensive studies on various cancer types, including lung cancer, breast cancer, and prostate cancer, investigating innovative treatment combinations and targeted therapies.

Advanced Melanoma Treatment
HER2-Positive Breast Cancer Therapy
Localized Colon Cancer Management

Emphasis on personalized treatment approaches and combination therapies to improve patient outcomes.

03 Respiratory and Allergic Conditions

Research focusing on allergic rhinitis, asthma management, and novel treatments for respiratory conditions, including standardization of allergen extracts and evaluation of new delivery systems.

Asthma Control Studies
Allergy Immunotherapy
Respiratory Treatment Innovation

Investigation of advanced therapeutic options for both acute and chronic respiratory conditions.

Back to Spain All countries